Mirum Pharmaceuticals (MIRM) Net Equity Issued and Repurchased (2020 - 2023)

Mirum Pharmaceuticals (MIRM) posted quarterly Net Equity Issued and Repurchased of $14.5 million for Q1 2023, down 47.54% quarter-over-quarter from $27.6 million in Q3 2022.

Mirum Pharmaceuticals (MIRM) Net Equity Issued and Repurchased (2020 - 2023) Analysis & Trends

Mirum Pharmaceuticals' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $14.5 million for Q1 2023.

  • In Q1 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $14.5 million; the TTM figure through Dec 2023 stood at $14.5 million (changed N/A YoY), while the FY2023 annual figure was $14.5 million, down 31.98% from the prior year.
  • Net Equity Issued and Repurchased for Q1 2023 stood at $14.5 million, down from $27.6 million in the prior quarter.
  • The five-year high for Net Equity Issued and Repurchased was $70.0 million in Q4 2020, with the low at $2.2 million in Q3 2020.
  • The 3-year median for Net Equity Issued and Repurchased is $27.6 million (2022), against an average of $31.1 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Mirum Pharmaceuticals 6.52 Bn 6.08 Bn 145.90 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2023 14.48 Mn
Mar 31, 2023 14.48 Mn
Sep 30, 2022 27.60 Mn
Sep 30, 2022 27.60 Mn
Jun 30, 2022 27.60 Mn
Jun 30, 2022 27.60 Mn
Dec 31, 2020 70.00 Mn
Dec 31, 2020 70.00 Mn
Sep 30, 2020 2.20 Mn
Sep 30, 2020 2.20 Mn
Mar 31, 2020 44.66 Mn
Mar 31, 2020 44.66 Mn